
{
  "Company Overview": {
    "Name": "Clinitech Laboratory Ltd",
    "Sector": "Healthcare",
    "Industry": "Healthcare",
    "Business Description": "Founded in 1990, Clinitech Laboratory Limited provides diagnostic and health testing and services. The company performs over 150 tests in its centers, categorized into Biochemical Tests, Immunology Tests, Hematology Tests, Molecular Biology Tests, Serology Tests, Microbiology Tests, and Histopathology Tests.",
    "Market Position": "Part of BSE SME IPO"
  },
  "Financial Metrics": {
    "Market Cap": "₹ 17.6 Cr.",
    "Current Price": "₹ 77.0",
    "High / Low": "₹ 121 / ₹ 63.0",
    "Stock P/E": "48.8",
    "Book Value": "₹ 41.8",
    "Dividend Yield": "0.00 %",
    "ROCE": "14.8 %",
    "ROE": "12.1 %",
    "Face Value": "₹ 10.0",
    "Debt-to-Equity Ratio": null //Not explicitly provided, needs further calculation from Balance Sheet data.
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sep 2023": {
        "Sales": "3.06",
        "Expenses": "2.78",
        "Operating Profit": "0.28",
        "OPM %": "9.15%",
        "Other Income": "0.02",
        "Interest": "0.04",
        "Depreciation": "0.19",
        "Profit before tax": "0.07",
        "Tax %": "14.29%",
        "Net Profit": "0.07",
        "EPS in Rs": "0.47"
      },
      "Sep 2024": {
        "Sales": "4.08",
        "Expenses": "3.52",
        "Operating Profit": "0.56",
        "OPM %": "13.73%",
        "Other Income": "0.05",
        "Interest": "0.04",
        "Depreciation": "0.31",
        "Profit before tax": "0.26",
        "Tax %": "15.38%",
        "Net Profit": "0.22",
        "EPS in Rs": "0.96"
      }
    },
    "Annual Results": {
      "Mar 2021": {
        "Sales": "4.55",
        "Expenses": "3.72",
        "Operating Profit": "0.83",
        "OPM %": "18.24%",
        "Other Income": "0.04",
        "Interest": "0.08",
        "Depreciation": "0.25",
        "Profit before tax": "0.54",
        "Tax %": "25.93%",
        "Net Profit": "0.40",
        "EPS in Rs": "6.00",
        "Dividend Payout %": "0.00%"
      },
      "Mar 2022": {
        "Sales": "6.38",
        "Expenses": "5.31",
        "Operating Profit": "1.07",
        "OPM %": "16.77%",
        "Other Income": "0.07",
        "Interest": "0.06",
        "Depreciation": "0.38",
        "Profit before tax": "0.70",
        "Tax %": "27.14%",
        "Net Profit": "0.51",
        "EPS in Rs": "3.40",
        "Dividend Payout %": "0.00%"
      },
      "Mar 2023": {
        "Sales": "6.35",
        "Expenses": "4.99",
        "Operating Profit": "1.36",
        "OPM %": "21.42%",
        "Other Income": "0.02",
        "Interest": "0.07",
        "Depreciation": "0.45",
        "Profit before tax": "0.86",
        "Tax %": "29.07%",
        "Net Profit": "0.61",
        "EPS in Rs": "4.07",
        "Dividend Payout %": "0.00%"
      },
      "Mar 2024": {
        "Sales": "6.40",
        "Expenses": "5.41",
        "Operating Profit": "0.99",
        "OPM %": "15.47%",
        "Other Income": "0.04",
        "Interest": "0.09",
        "Depreciation": "0.44",
        "Profit before tax": "0.50",
        "Tax %": "26.00%",
        "Net Profit": "0.37",
        "EPS in Rs": "2.20",
        "Dividend Payout %": "0.00%"
      }
    },
    "Balance Sheet Highlights": {
      "Mar 2021": {
        "Equity Capital": "0.67",
        "Reserves": "0.72",
        "Borrowings": "0.54",
        "Other Liabilities": "0.80",
        "Total Liabilities": "2.73",
        "Fixed Assets": "0.84",
        "CWIP": "0.08",
        "Investments": "0.09",
        "Other Assets": "1.72",
        "Total Assets": "2.73"
      },
      "Mar 2022": {
        "Equity Capital": "1.50",
        "Reserves": "0.35",
        "Borrowings": "0.89",
        "Other Liabilities": "0.94",
        "Total Liabilities": "3.68",
        "Fixed Assets": "1.65",
        "CWIP": "0.41",
        "Investments": "0.14",
        "Other Assets": "1.48",
        "Total Assets": "3.68"
      },
      "Mar 2023": {
        "Equity Capital": "1.50",
        "Reserves": "0.88",
        "Borrowings": "1.03",
        "Other Liabilities": "2.62",
        "Total Liabilities": "6.03",
        "Fixed Assets": "1.33",
        "CWIP": "0.56",
        "Investments": "2.02",
        "Other Assets": "2.12",
        "Total Assets": "6.03"
      },
      "Mar 2024": {
        "Equity Capital": "1.68",
        "Reserves": "1.87",
        "Borrowings": "0.87",
        "Other Liabilities": "1.19",
        "Total Liabilities": "5.61",
        "Fixed Assets": "1.71",
        "CWIP": "0.94",
        "Investments": "0.07",
        "Other Assets": "2.89",
        "Total Assets": "5.61"
      },
      "Sep 2024": {
        "Equity Capital": "2.28",
        "Reserves": "7.27",
        "Borrowings": "0.01",
        "Other Liabilities": "1.48",
        "Total Liabilities": "11.04",
        "Fixed Assets": "1.77",
        "CWIP": "1.00",
        "Investments": "0.07",
        "Other Assets": "8.20",
        "Total Assets": "11.04"
      }
    },
    "Cash Flow Summaries": {
      "Mar 2021": {
        "Cash from Operating Activity": "0.38",
        "Cash from Investing Activity": "0.54",
        "Cash from Financing Activity": "-0.88",
        "Net Cash Flow": "0.04"
      },
      "Mar 2022": {
        "Cash from Operating Activity": "0.96",
        "Cash from Investing Activity": "-1.47",
        "Cash from Financing Activity": "0.29",
        "Net Cash Flow": "-0.22"
      },
      "Mar 2023": {
        "Cash from Operating Activity": "1.25",
        "Cash from Investing Activity": "-0.65",
        "Cash from Financing Activity": "0.09",
        "Net Cash Flow": "0.68"
      },
      "Mar 2024": {
        "Cash from Operating Activity": "0.11",
        "Cash from Investing Activity": "-0.64",
        "Cash from Financing Activity": "0.45",
        "Net Cash Flow": "-0.08"
      }
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth": {
        "10 Years": null,
        "5 Years": null,
        "3 Years": "12%",
        "TTM": "1%"
      },
      "Compounded Profit Growth": {
        "10 Years": null,
        "5 Years": null,
        "3 Years": "-1%",
        "TTM": "-41%"
      },
      "Stock Price CAGR": {
        "10 Years": null,
        "5 Years": null,
        "3 Years": null,
        "1 Year": null
      }
    },
    "Liquidity Ratios": null, //Not explicitly provided, needs calculation
    "Profitability Ratios": {
      "Return on Equity": {
        "10 Years": null,
        "5 Years": null,
        "3 Years": "22%",
        "Last Year": "12%"
      },
      "ROCE %": {
        "Mar 2021": "32.55%",
        "Mar 2022": "30.24%",
        "Mar 2023": "14.81%"
      }
    },
    "Valuation Ratios": null, //Needs calculation
    "Other Ratios": {
      "Debtor Days": {
        "Mar 2021": "44.92",
        "Mar 2022": "20.60",
        "Mar 2023": "28.17",
        "Mar 2024": "34.22"
      },
      "Inventory Days": {
        "Mar 2021": "32.21",
        "Mar 2022": "40.28",
        "Mar 2023": "43.68",
        "Mar 2024": "92.91"
      },
      "Days Payable": {
        "Mar 2021": "164.61",
        "Mar 2022": "130.90",
        "Mar 2023": "124.79",
        "Mar 2024": "116.14"
      },
      "Cash Conversion Cycle": {
        "Mar 2021": "-87.48",
        "Mar 2022": "-70.03",
        "Mar 2023": "-52.95",
        "Mar 2024": "10.99"
      },
      "Working Capital Days": {
        "Mar 2021": "48.13",
        "Mar 2022": "25.74",
        "Mar 2023": "9.77",
        "Mar 2024": "57.60"
      }
    }
  },
  "Peer Comparison": {
    "Status": "Loading peers table ..."
  },
  "Other Insights": {
    "Pros": [
      "Company has reduced debt.",
      "Company is almost debt free."
    ],
    "Cons": [
      "Though the company is reporting repeated profits, it is not paying out dividend"
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "Shareholding Pattern": {
      "Sep 2024": {
        "Promoters": "61.58%",
        "FIIs": "0.32%",
        "Public": "38.11%",
        "No. of Shareholders": "346"
      }
    },
    "Notes on Shareholding Data": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
  },
  "Documents": {
    "Announcements": [
      {
        "Title": "Submission Of Statement Of Deviation(S) Or Variation(S) Pursuant To Regulation 32 Of SEBI (LODR) Regulations 2015",
        "Date": "13 Nov"
      },
      {
        "Title": "Non Applicability Of Related Party Transactions",
        "Date": "13 Nov"
      },
      {
        "Title": "Outcome Of The Board Meeting Held On Wednesday, November 13, 2024.",
        "Date": "13 Nov"
      },
      {
        "Title": "Board Meeting Intimation for Financial Results For The Period Ended September 30, 2024",
        "Date": "6 Nov"
      }
    ],
    "Annual Reports": "No data available."
  }
}
